Pharmaceuticals

An Australian biotech's breakthrough study on fucoidan, a seaweed compound, offers a safe, clinically-proven new option for men suffering from BPH.

A new partnership in the booming peptide market signals a major shift. Novadose and Pure Pharmaceuticals are betting that future success won't just come from discovery, but from demonstrating unimpeachable quality and transparency.

A perfect storm of wonder drugs, AI-driven billing, and flawed policy is pushing employer health costs to a 15-year high, forcing a radical rethink of benefits.

As over 40% of Americans skip meds due to cost, a new report reveals the pivotal, money-saving role of health-system pharmacists. Here's how they help.

An upcoming summit for LGMD isn't just another conference. It's a key signal that patient advocacy, biotech innovation, and regulatory shifts are converging.

FDA clears a pivotal study for Medicus Pharma's SkinJect, a microneedle patch offering new hope for Gorlin Syndrome and a new playbook in biotech strategy.

Small biotech Veru Inc. is betting its future on improving blockbuster weight-loss drugs, targeting the hidden cost of muscle loss in a billion-dollar market.

A novel partnership aims to create the first drug for ReNU syndrome, a condition found in 2024, potentially redefining rare disease drug development.

With a new CMO and fresh funding, Spero Therapeutics is betting big on its immunology asset SP001. Can Dr. Zack guide it to success in a competitive field?

Following a strategic merger and a $200M financing round, Yarrow Bioscience is advancing a novel drug for autoimmune thyroid disease. But can it disrupt a market dominated by incumbents?

A federal jury found investment firm RA Capital willfully misappropriated trade secrets from Yale, a stark reminder for investors of the risks of lax IP due diligence.

Promising early data for BBT001 suggests a potent combination of rapid relief and quarterly dosing, but can the biotech startup navigate the long road from pilot to production?

Leveraging its global dominance in human medicine, Jiangxi Bio is entering the booming veterinary market with a new production line, a key move in its growth strategy.

With its $2.2B acquisition of Forte, argenx adds a first-in-class antibody, FB102, expanding its Vision 2030 strategy to redefine autoimmune care.

A positive EMA opinion for Minoryx's NEZGLYAL offers the first-ever drug therapy for a fatal childhood disease, highlighting a key regulatory pathway.

Ridgetech’s new leadership role in a key Chinese biomedical hub is no accident. It’s the result of turning strict drug traceability rules into a tech-driven advantage.

Samsung Epis Holdings reports solid growth driven by its biosimilar portfolio, but the real story is its strategic pivot to next-gen cancer drugs and global expansion.

Ipsen's BOLD trial for biliary atresia failed, a blow to families. But in the data from this setback lies a critical roadmap for future research.